EUVIMEDEUVIMED entdecken
Klinische Studie

Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission

Dandan Wang, Xiaobing Wang, Binghe Tan, Xin Wen, Songying Ye, Yingyi Wu, Xuan Cao, Xin Zhang, Chun Wang, Linyu Geng, Huayong Zhang, Xuebing Feng und 7 weitere

Med · 2025-10 · 6 (10) · 100749

DOI: 10.1016/j.medj.2025.100749 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Med, 2025-10. Verfasst von Dandan Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Lupus Erythematosus, Systemic, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Autoreactive B cells play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The aim of this study is to assess the safety of allogeneic chimeric antigen receptor (CAR)-T cells for patients with lupus. This study was registered at ClinicalTrials.gov (NCT05859997). METHODS: In this study, 3 patients with refractory and severe SLE with multi-organ involvement were enrolled. Genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells were infused intravenously at a dose of 1 million cells per kilogram of body weight. The safety indices, including the occurrence of graft-versus-host disease (GvHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS), were evaluated. The proliferation of CAR+ T cells and the number of peripheral B cells were assessed. The clinical efficacy was also assessed based on the SELENA-SLEDAI, SLEDAI-2K, BILAG, clinical SLE responder index-4 (SRI-4), and DORIS remission index. FINDINGS: Between August 2023 and October 2023, 3 patients with SLE were enrolled and completed a 12-month follow-up. No patient underwent GvHD, CRS, or ICANS, and no severe adverse events were recorded. CAR+ T cells expanded in vivo, peaking at day 14, and then declined. The percentage of B cells in lymphocytes and the absolute circulating B cell counts were profoundly decreased. Patient 1 withdrew from the study at month 1 due to unresolved and severe thrombocytopenia and the need for the addition of an immunosuppressive drug. SELENA-SLEDAI and SLEDAI-2K scores declined, and all the patients reached SRI-4 remission at the last visit. CONCLUSIONS: In patients with severe and refractory SLE, allogeneic CAR-T cell therapy showed profound safety and clinical efficacy for disease remission. FUNDING: 82320108010, 31821003, 81930043, 82330055, and U24A20380.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Immunotherapy, AdoptiveLupus Erythematosus, SystemicReceptors, Chimeric AntigenAdultFemaleHumansMaleMiddle AgedB-LymphocytesCytokine Release SyndromeGraft vs Host DiseaseRemission InductionTreatment Outcome

Stichwörter der Autor:innen

CAR-T cellTranslation to patientsallogeneicremissionsafetysystemic lupus erythematosus

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of Rheumatology and Immunology, National Key Laboratory for Immunity and Inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai 200241, China; BRL Medicine, Inc.,…
  • BRL Medicine, Inc., Shanghai, China.
  • Committee on Cancer Biology, The University of Chicago, Chicago, IL 60637, USA.
  • Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. Electronic address: lingyunsun@nju.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Shanghai Municipal Health Commission
  • Nanjing Drum Tower Hospital
  • Jiangsu Commission of Health
  • Science and Technology Commission of Shanghai Municipality
  • Basic Research Program of Jiangsu Province

Zitieren

APA

Wang, D., Wang, X., Tan, B., Wen, X., Ye, S., Wu, Y., Cao, X., Zhang, X., Wang, C., Geng, L., Zhang, H., Feng, X., Zheng, B., He, Y., Liu, M., Wu, X., Du, B., Sun, L., & Xu, H. (2025). Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med, 6(10), 100749. https://doi.org/10.1016/j.medj.2025.100749

Vancouver

Wang D, Wang X, Tan B, Wen X, Ye S, Wu Y, et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med. 2025;6(10):100749. doi:10.1016/j.medj.2025.100749

BibTeX
@article{Wang2025,
  author = {Wang, Dandan and Wang, Xiaobing and Tan, Binghe and Wen, Xin and Ye, Songying and Wu, Yingyi and Cao, Xuan and Zhang, Xin and Wang, Chun and Geng, Linyu and Zhang, Huayong and Feng, Xuebing and Zheng, Biao and He, Yanran and Liu, Mingyao and Wu, Xin and Du, Bing and Sun, Lingyun and Xu, Huji},
  title = {Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission},
  journal = {Med},
  year = {2025},
  volume = {6},
  number = {10},
  pages = {100749},
  doi = {10.1016/j.medj.2025.100749}
}
Kostenlos starten →